0.00
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About DNAPrint Genomics
Its shares trade under the ticker DNAG. It has been listed since 23 February 2001. In the fiscal year to 31 December 2006, it reported revenue of $2.4m and a net loss of $12.3m. At that date it held total assets of $10.3m and shareholders' equity of −$3.7m.
DNAPrint Genomics, Inc. engages in the research and development of genomics-based products and services for biomedical and forensics. The company is headquartered in Sarasota, Florida. The company went IPO on 2001-02-23. As of March 15, 2007, the Company’s pharmacogenomics products were still in development. The firm generates revenues in its consumer, forensic and genotyping services, but these services have not resulted in the generation of significant revenues. During the year ended December 31, 2006, the Company’s revenues were from the sales of its ancestry product, AncestryByDNA and genotyping services. The firm provides services that range from sequencing and genotyping to the entire process of single nucleotide polymorphisms (SNP) discovery to large industrial customers. Contract genotyping is the process of reading a genetic sequence and identifying differences in the sequence letters. This information helps researchers understand how human differences are expressed at the gene level.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Feb 2001
- Employees
- 24
Leadership
Pay as last reported
- Dr. Hector GomezChairman of the Board, Chief Medical Officer, since 2002$757,948
- Karen SurplusChief Accounting Officer
- Dr. Tony FrudakisChief Scientific Officer, Secretary, Director$708,487
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- DNAPrint Genomics Inc has several strengths that contribute to its success in the genomics industry. Firstly, the company has a strong patent portfolio, allowing it to protect and monetize its genetic analysis technologies. This provides a competitive advantage and ensures a unique offering to customers.
- Secondly, DNAPrint Genomics Inc has a team of highly skilled and experienced scientists and researchers. Their expertise and knowledge in genomics enable the company to develop innovative solutions and stay at the forefront of the industry.
- Finally, the company has established strategic partnerships with leading academic institutions and research organizations. These collaborations provide access to cutting-edge research and resources, enhancing DNAPrint Genomics Inc's capabilities and credibility in the market.
Weaknesses
- Despite its strengths, DNAPrint Genomics Inc faces some weaknesses that may hinder its growth. One weakness is the high cost associated with the development and commercialization of genetic analysis technologies. This can limit the company's ability to invest in research and development, as well as pricing its products competitively.
- In addition, DNAPrint Genomics Inc heavily relies on third-party suppliers for key components and materials. Any disruptions or delays in the supply chain may impact the company's operations and ability to deliver products on time.
- Lastly, the genomics industry is highly competitive, with numerous established players and new entrants. DNAPrint Genomics Inc needs to continuously differentiate itself, innovate, and adapt to changes in the industry to stay ahead of the competition.
Opportunities
- DNAPrint Genomics Inc has several opportunities to expand its business and market presence. One opportunity lies in the growing demand for personalized medicine. The company can leverage its genetic analysis technologies to offer tailored solutions for healthcare providers and patients, contributing to improved healthcare outcomes.
- Another opportunity arises from the increasing adoption of genetic testing for ancestry and genealogy purposes. DNAPrint Genomics Inc can develop and market consumer-focused genetic testing kits, catering to the interest in understanding one's genetic heritage and family history.
- Furthermore, the company can explore collaborations with pharmaceutical companies to identify genetic markers for drug response and develop personalized therapies. This can open up new revenue streams and enable DNAPrint Genomics Inc to contribute to the advancement of precision medicine.
Threats
- DNAPrint Genomics Inc faces various threats that may impact its operations and financial performance. One significant threat is the evolving regulatory landscape in the genomics industry. Changes in regulations and privacy laws can increase compliance costs and limit the company's ability to collect and use genetic data.
- Additionally, there is a risk of intellectual property disputes and patent infringements, especially as the genomics industry grows more competitive. Legal battles can be costly and time-consuming, diverting resources and potentially damaging DNAPrint Genomics Inc's reputation.
- Lastly, technological advancements and new discoveries in genomics may render DNAPrint Genomics Inc's current offerings and technologies obsolete. The company needs to continuously invest in research and development to stay ahead of the curve and ensure its relevance in the rapidly evolving genomics landscape.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.